Antibiotic Treatment foLlowing Surgical drAinage of Perianal abScess; the ATLAS Trial

Perianal Fistula Clinical Trial

— ATLAS  

Official title:

Antibiotic Treatment foLlowing Surgical drAinage of Perianal abScess; the ATLAS Trial, a Double-blind, Placebo-controlled, Randomized Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05385887
• Other study ID #: NL75540.018.20
• Secondary ID: 2020-004449-35
• Status: Recruiting
• Phase: N/A
• Start date: December 23, 2021
• Est. completion date: August 1, 2025

Study information

• Verified date: November 2023
• Source: Proctos Kliniek
• Contact: Ingrid M Han-Geurts, Dr.
• Phone: 030 225 0260
• Email: i.han[@]proctoskliniek.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Rationale: Perianal fistula is a burdening disease with an annual prevalence of 2/100.000 in the Dutch population. More than 90% of crypto-glandular fistulas originate from anorectal abscess. Despite adequate drainage of anorectal abscess up to 83% recurs or results in an anal fistula, the majority developing within 12 months. Up till now it is not common practice to routinely administer prophylactic antibiotics to prevent anal fistula development.\ Objective: The objective of this trial is to establish if adding antibiotic treatment to surgical drainage of perianal abscess results in less perianal fistulas. Study design: The study concerns a double-blind, placebo-controlled, randomized, multicenter trial with treatment of perianal abscess by surgical drainage alone or combined with antibiotic treatment. Patients will be accrued by all participating clinics. The design involves allocation of all appropriate consecutive patients with a primary occurrence of perianal abscess to surgical drainage followed by either antibiotics or placebo. Data will be analyzed on 'intention to treat' basis in case patients are not subjected to the randomized treatment modality. Study population: Men and women of 18 years and older who present for the first time with a perianal abscess. Intervention (if applicable): The antibiotic group receives 7 days of oral metronidazole (500 mg every eight hours) and ciprofloxacin (500 mg every twelve hours) in addition to surgical drainage. The other group receives surgical drainage and postoperatively identical placebo tablets. Main study parameters/endpoints: Primary outcome measure is development of a perianal fistula. Secondary outcome measures are quality of life at 12 months measured with the EQ-5D-5L with Dutch rating. Further: in-hospital direct and indirect costs and out-of hospital postoperative costs, need of repeated drainage, patient related outcome (PRO) and clinical outcome measures. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: For this study, patients are asked to take part in a study comparing the addition of antibiotic treatment to surgical drainage of perianal abscess. Patients will not be burdened by extra hospital visits. At baseline participants will complete PRO questionnaires. Also at 1 week and 3, 6 and 12 months participants will fulfill the PRO questionnaires. These will be send to them by email and will take approximately 10 minutes each time.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 298
• Est. completion date: August 1, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men and women aged 18 years or older
• Eligible for e-mail questionnaires
• Sufficient understanding of the Dutch written language (reading and writing)
• Obtained written informed consent

Exclusion Criteria:

• A coexistent anorectal fistula
• Secondary or recurrent anorectal abscess
• Presence of an internal fistula opening
• Any additional surgical procedure performed during the same session
• Previous (peri)anal surgery
• Inflammatory bowel disease
• History of radiation of the pelvic area
• Anorectal malignancy
• Immunodeficiency
• Kidney failure (eGFR <30ml/min)
• Valvular heart disease
• Pregnancy or lactation
• Postoperative antibiotic prophylaxis indicated for another reason
• Immunosuppressive medication at the time of surgery
• Allergy to metronidazole or ciprofloxacin
• Not able or trouble with swallowing pills
• Concomitant use of:
• Tizanidine, theophylline, clozapine, olanzapine, pirfenidone, carbamazepine, agomelatine (these are all CYP1A2 substrates, ciprofloxacin is an inhibitor)
• Amiodarone, erythromycin, sotalol, azithromycin, citalopram, escitalopram, flecainide, fluconazole, haloperidol >5mg/day, methadone, ondansetron (concerning prolonged QT interval in combination with ciprofloxacin)
• Lithium (can cause toxic levels with metronidazole)
• Lopinavir/ritonavir, ritonavir capsules, temsirolimus, disulfiram (antabuse), mebendazole (can cause serious side effects, confusion and psychosis in combination with metronidazole)
• Corticosteroids (in combination with ciprofloxacin higher risk of tendinitis and tendon rupture).

Related Conditions & MeSH terms

• Abscess
• Drain Abscess
• Fistula
• Perianal Abscess
• Perianal Fistula

Intervention

Drug:
• Ciprofloxacin 500 mg
One tablet of 500mg Ciprifloxacine, twice a day
• Metronidazole 500 mg
One tablet of 500mg Metronidazole, three times a day
• Placebo
Placebo tablets

Locations

Country	Name	City	State
Netherlands	Flevoziekenhuis	Almere
Netherlands	OLVG	Amsterdam	North-Holland
Netherlands	University Medical Center location AMC	Amsterdam
Netherlands	Rode Kruis ziekenhuis	Beverwijk	Noord-Holland
Netherlands	Proctos kliniek	Bilthoven	Utrecht
Netherlands	Amphia hospital	Breda	North-Brabant
Netherlands	IJsselland ziekenhuis	Capelle Aan Den IJssel
Netherlands	Albert Schweitzer ziekenhuis	Dordrecht	Zuid-Holland
Netherlands	Dijklander hospital	Hoorn	North-Holland
Netherlands	Elisabeth-TweeSteden ziekenhuis	Tilburg	Noord-Brabant
Netherlands	Diakonessenhuis	Utrecht

Sponsors (2)

Lead Sponsor	Collaborator
dr. IJM Han-Geurts	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Perianal fistula at 1 year follow up	A perianal fistula is diagnosed based on findings from physical examination or by a telephone call after 12 months were the doctor asks for symptoms as serosanguinous discharge and pain. An external opening with or without serosanguilent discharge is considered a fistula. In case of doubt an endoanal ultrasonography or MRI is performed.; So: yes/no fistula (dichotomous parameter)	1 year
Secondary	Quality of life at 12 months measured with the EQ-5D-5L with Dutch rating.	The EQ-5D-5L is a generic Health Related Quality of Life (HRQoL) measure, which is broadly used in economic evaluation. The instrument examines a patient's HRQoL on the day of the interview. It consists of the EQ-5D-5L descriptive system and the EQ-Visual Analogue Scale. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has five levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses to the 5 items result in a patient's health state that can be transformed into an index score representing health-related quality of life, ranging between 0 (death) and 1 (full health). These index scores are combined with length of life to calculate the QALY. The EQ-VAS records the patient's self-rated health with endpoints labelled 'the best health you can imagine' at the top and 'the worst health you can imagine' at the bottom.	1 year
Secondary	In-hospital direct and indirect costs and out-of hospital posteroperative costs	In-hospital direct and indirect costs (measured with iPCQ and iMCQ) and out-of hospital postoperative costs.	1 year
Secondary	Need of repeated drainage		1 year
Secondary	PROMs	Patient related outcome (PRO) are complaint reduction assessed by a proctology specific validated patient-related outcome measure, the proctoPROM(14). This was recently developed and validated at Proctos Clinic. At baseline participants will complete PRO questionnaires. Also at 1 week and 3, 6 and 12 months participants will fulfill the PRO questionnaires. These will be send to them by email with access to a web tool (Castor). If the patient does not have an email account, the questionnaires will be send the patients' home address, accompanied by a return envelope provided with postage stamps and the address of the hospital.	1 year
Secondary	Day of discharge from hospital	Day of discharge from hospital;	1 year
Secondary	Postoperative complications	Complications (postoperative bleeding, urinary retention requiring catheterisation, emergency reoperation, anal stenosis and fecal incontinence) including death and cause of death within 30 days will be reported using the Clavien-Dindo classification of surgical complications(15).	1 year
Secondary	Recurrent abscess	(Recurrent) abscess within one year. Yes/no (dichotomous)	1 year
Secondary	Duration of absence from work	Duration of absence from work. Amound of days is recorded (continuous scale)	1 year